Changes in brain cholinesterases in senile dementia of Alzheimer type.
about
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's DiseaseBasal forebrain control of wakefulness and cortical rhythms.Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodentExcessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activityDetermination of allelic expression of SNP rs1880676 in choline acetyltransferase gene in HeLa cellsPositron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's diseaseRadiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity.Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.Genetic risk factors in Alzheimer's diseaseRivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.The noradrenergic system in Alzheimer and multi-infarct dementiasPharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNSA novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's diseaseComparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease.Sympathetic sprouting in visual cortex stimulated by cholinergic denervation rescues expression of two forms of long-term depression at layer 2/3 synapses.Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status.A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysisNeurobiology of butyrylcholinesterase.Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.Cholinergic imbalance in the multiple sclerosis hippocampus.Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variationSynergistic inhibition of butyrylcholinesterase by galantamine and citalopram.Biochemical differentiation of cholinesterases from normal and Alzheimer's disease cortex.Rivastigmine in vascular dementia.EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.Selective hippocampal cholinergic deafferentation impairs self-movement cue use during a food hoarding taskComparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's studyCholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's diseaseMolecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.
P2860
Q26744105-FC28212A-FF98-4972-9D07-F7C4E9D926D2Q27319516-29BF3117-4179-4A75-A401-DD4428C285E2Q28578059-EADC736A-CDEB-4B76-9106-41DC6166AFF1Q28586552-F143F888-90EF-4708-8C94-13762DA74342Q30409958-07991A9B-5E38-4D78-922D-E2CC1BC28343Q30497749-543D30ED-B900-4EC7-AD39-2AC03E831A30Q31930873-919F7A89-CBDE-443E-892A-5A0FE30DD626Q33291757-6E02727F-4A0F-4FBA-9EA4-B2EEB819A03AQ33588353-9AD01538-8278-48CA-8366-3E8844294BCCQ33596451-40AE2D43-416C-412F-831D-BA766B07B0FBQ33708963-6AF21AEF-9021-4933-8D97-8A5A7289A8FFQ33750604-754B47F5-4A07-4AF2-8A5D-48295A62CF42Q33755706-BCFE668F-8F4F-45CD-90AD-DE917A5AE84BQ33828536-F2F0937F-3ED9-41BC-BC64-9E5373FF7391Q33894621-743073F1-108B-429F-A56C-4B483D01D833Q33896054-18E5F3FC-512E-4464-A62D-BF41B330FBB1Q33937187-528B98ED-A560-470A-B120-002683E73162Q33943532-F9156E90-6C5A-4E86-BB53-BF3D3E4F695DQ33968308-3F5B1FCA-0EA9-46E1-A79B-5012CE51680BQ34119518-A3D7E46B-CB92-4A47-B8D0-ED05018BD930Q34521949-22D57EC8-8F20-4E67-8757-837B84DCAFA1Q34710672-567F3D43-328F-4A33-B697-0BB100F050A8Q34743671-C5051810-17FF-4C90-A84C-799A1081EB99Q35058510-2EC53DF8-B332-4435-B266-6D3C615A5445Q35060833-04975DD3-B951-4FFE-9BC1-9D72E1D681E2Q35066849-027EA643-DF09-4991-B46E-CC7DA5913403Q35106861-7942635A-39BA-4984-922C-2CDAF45AE547Q35200654-710F8D5B-5C7A-4BAC-88B4-EF26D9E7423AQ35236550-FFF4C702-C652-4DAE-B2CC-FD667598DC1AQ35428213-B944A9A2-E598-4A1A-BA9A-A0EA0B825BA6Q35487636-3153B263-827A-4939-9E79-1903FBB116A3Q35687175-CAA39BEC-CA6F-4A65-9223-7AE6909C1647Q35757336-F6B0480A-CEAC-4A3A-A106-D12C30F4B848Q35784086-49744F3D-6D1F-436C-86AC-1E77C31AD0EDQ35987359-04D1888F-1924-48F1-A95F-5EBCD3EE1816Q36005502-6684D1C1-18DB-4A93-8440-076B4326E6B3Q36247233-D14FA789-E60E-4B7D-9D09-11CCCB47322AQ36475090-D3D9C2BF-A1A4-4F4E-8D37-54639ACC8091Q36601142-257EA4E7-FA5F-48A0-BECC-8CC04C95AC29Q36724965-B08912FF-60DA-44E4-88C4-166822092EF9
P2860
Changes in brain cholinesterases in senile dementia of Alzheimer type.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年学术文章
@wuu
1978年学术文章
@zh-cn
1978年学术文章
@zh-hans
1978年学术文章
@zh-my
1978年学术文章
@zh-sg
1978年學術文章
@yue
1978年學術文章
@zh
1978年學術文章
@zh-hant
name
Changes in brain cholinesterases in senile dementia of Alzheimer type.
@en
Changes in brain cholinesterases in senile dementia of Alzheimer type.
@nl
type
label
Changes in brain cholinesterases in senile dementia of Alzheimer type.
@en
Changes in brain cholinesterases in senile dementia of Alzheimer type.
@nl
prefLabel
Changes in brain cholinesterases in senile dementia of Alzheimer type.
@en
Changes in brain cholinesterases in senile dementia of Alzheimer type.
@nl
P2093
P2860
P1476
Changes in brain cholinesterases in senile dementia of Alzheimer type.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2990.1978.TB00545.X
P577
1978-07-01T00:00:00Z